A new 26-floor tower is expected to rise in the Texas Medical Center and deliver in 2027. Rendering courtesy of Houston Methodist

Construction has begun on a $1.4 billion hospital tower at the Texas Medical Center.

Houston Methodist’s 26-story Centennial Tower will be connected to the Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. Among other things, the new tower will feature a larger emergency department and hundreds of patient beds. It’s scheduled to open in 2027.

“Together, the towers will add an impressive profile to the Texas Medical Center skyline,” says Dr. Marc Boom, president and CEO of Houston Methodist. “We are building this for our community, showing our commitment to the future of health care at Houston Methodist as we continue leading medicine for decades to come.”

The new tower will connect to the Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. Rendering courtesy of Houston Methodist

Highlights of Centennial Tower include:

  • A new emergency department with 54 beds and additional suites.
  • Nearly 400 patient beds, including 175 new beds and 207 beds to replace those in Houston Methodist’s Main building. That building and the West Pavilion eventually will be torn down.
  • New space for transplant medicine, intermediate care, and surgical intensive care.
  • Nine operating rooms, including two new operating rooms.
  • A 14th-floor rooftop garden.

The adjacent Paula and Joseph C. “Rusty” Walter III Tower houses the Houston Methodist DeBakey Heart & Vascular Center and the Houston Methodist Neurological Institute.

Albany, New York-based design firm EYP is Centennial Tower’s architect, and Houston-based Vaughn Construction is the general contractor.

Centennial Tower’s 14th floor will feature an outdoor rooftop garden. Rendering courtesy of Houston Methodist

EYP recently filed for Chapter 11 bankruptcy protection. In connection with the voluntary bankruptcy filing, Tampa, Florida-based Ault Alliance has agreed to buy the majority of EYP’s assets (including customer contracts) for $67.7 million, plus the assumption of “significant” liabilities. Ault plans to retain EYP’s staff. If the deal goes through, EYP would operate under its current brand name.

“EYP is a good candidate to use the protections that a Chapter 11 process provides,” says Kefalari Maso, interim CEO of EYP. “Our business is as strong as it has ever been, and the advantages … are that it allows us to continue doing the work we love while quickly moving through a sale process that further strengthens our financial position, allowing us to shape a future that matches our success over the last few years.”

The tower's plans include a new emergency department with 54 beds and additional suites. Rendering courtesy of Houston Methodist

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”